ArticleBMC women's health2025
The effect of para-aortic lymphadenectomy on survival in early stage endometrioid grade 3 and non-endometrioid endometrial cancers.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Impact of Pelvic Lymph Node Count in Surgically Staged Endometrial Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- Survival benefit of extended lymphadenectomy in endometrial cancer: a meta-analysis with risk-stratified subgroup analysis.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic and therapeutic significance of para-aortic lymphadenectomy remains controversial due to conflicting evidence in the literature. There are limited studies specifically examining patients with grade 3 endometrioid and non-endometrioid histologies. In this study, we aimed to investigate the effect of adding para-aortic lymphadenectomy to pelvic lymphadenectomy on survival outcomes in patients with early-stage uterine-confined grade 3 endometrioid and non-endometrioid endometrial carcinoma.
methodsThis retrospective cohort study included 182 patients with FIGO 2009 stage I-II, pathologically node-negative grade 3 endometrioid or non-endometrioid endometrial cancers treated at a single tertiary center between 1995 and 2025. Patients underwent either pelvic lymphadenectomy (PLND) alone 85 (46.7%) or combined pelvic and para-aortic lymphadenectomy (PPLND) 97 (53.3%). Clinicopathological data and survival outcomes were compared. Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards models were used to assess disease-free survival (DFS) and overall survival (OS).
resultsThe median duration of follow-up in the overall cohort was 60.5 months, while the median time to recurrence among patients who experienced disease relapse was 52.0 months. No significant difference was observed in DFS or OS between patients who underwent PLND alone and those who underwent PPLND. The hazard ratio (HR) for DFS was 0.88 (95% CI: 0.47-1.64, p = 0.690), and similarly, the HR for OS was 0.98 (95% CI: 0.60-1.62, p = 0.941). In univariate and multivariate Cox regression analysis, non-endometrioid histology was associated with worse DFS and OS (p:<0.001, p:0.04). While there was no significant difference in DFS in patients aged ≥ 60 years, a three-fold worse OS outcome was found (HR = 3.08; 95% CI: 1.59-5.99; p < 0.001). Other clinicopathological parameters, such as FIGO stage, depth of myometrial invasion, presence of lymphovascular invasion (LVSI), cytology results, surgical approach, and extent of lymphadenectomy, did not show a significant association with DFS or OS in multivariate analysis (all p > 0.05).
conclusionsIn patients with early-stage, node-negative grade 3 endometrioid and non-endometrioid endometrial cancers, the addition of para-aortic lymphadenectomy to pelvic dissection did not confer a survival advantage. Moreover, older age (≥ 60 years) was associated with significantly worse overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.